Loading
Viral Infections and Vectors / Viral Infections and Outbreaks Research / Mosquito Borne Diseases and Control · Journal article
Clinical Immunology Communications · August 20, 2026
Raises a question worth testing. It does not answer one.
This is a structured narrative review synthesizing evidence on barriers to broadly protective hantavirus vaccines, proposing an integrated framework combining structural vaccinology, immunology, and One Health principles. The source identifies key obstacles—antigenic diversity, immune evasion, and incomplete correlates of protection—and raises the hypothesis that success depends on targeting conserved epitopes and achieving composite immune responses, but does not present new empirical data or clinical trial results to test this framework.
Structured critical narrative review. Literature on hantavirus infections, immune responses, and vaccine development; no primary patient cohort enrolled.
Broadly protective vaccine development constrained by extensive antigenic diversity and viral immune-evasion mechanisms Neutralizing antibodies remain leading correlate of homologous protection; composite correlates involving humoral, cellular, innate, and memory responses needed for broader protection Recent structural studies identifying conserved glycoprotein epitopes and broadly neutralizing antibodies support structure-guided antigen design
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This framework is intended to inform next-generation vaccine development strategy but does not provide evidence to guide clinical practice or define specific immunization recommendations at this time.
A narrative review synthesizing existing evidence to propose a framework for future vaccine development, raising questions about broadly protective hantavirus vaccines rather than reporting new empirical results.
As stated by the source record.
This framework is intended to inform next-generation vaccine development strategy but does not provide evidence to guide clinical practice or define specific immunization recommendations at this time.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background Hantaviruses are globally distributed zoonotic pathogens that cause hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS), yet no broadly protective vaccine is currently available. This review critically examines why broadly protective hantavirus vaccines have remained elusive and presents an integrated framework that combines immunological barriers, structural vaccinology, and One Health perspectives to inform next-generation vaccine development. Methodology A structured critical narrative review was conducted following the Scale for the Assessment of Narrative Review Articles (SANRA) framework. Literature was retrieved from PubMed, Scopus, Web of Science, and Google Scholar (1996-2026). Evidence from human studies, experimental infection models, structural biology investigations, mechanistic immunology studies, and preclinical and clinical vaccine research was critically synthesized to evaluate protective immunity, correlates of protection, antigenic diversity, immune escape, and emerging strategies for broad vaccine protection. Results Current evidence indicates that broadly protective vaccine development is constrained by extensive antigenic diversity, viral immune-evasion mechanisms, incomplete validation of immune correlates of protection, and limited understanding of durable cross-protective immunity. Although neutralizing antibodies remain the leading correlate of homologous protection, accumulating evidence supports composite correlates involving coordinated humoral, cellular, innate, and memory immune responses for broader protection. Recent structural studies identifying conserved glycoprotein epitopes and broadly neutralizing antibodies have strengthened the biological rationale for structure-guided antigen design and rational immunogen engineering. Conclusion This review highlights that the pathway to broadly protective hantavirus vaccines depends less on new vaccine platforms than on integrating structural vaccinology, systems immunology, and One Health principles to target conserved viral vulnerabilities and achieve durable protection against both established and emerging hantaviruses.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.